ArriVent’s stock plummets on Phase III NSCLC trial failure
ArriVent BioPharma’s stock has dropped 46% after a Phase III trial of its non-small cell lung cancer (NSCLC) candidate failed …
Post
-
-
Cerevance’s novel Parkinson’s drug nets a Phase III win
Boston-based biotech Cerevance’s first-in-class Parkinson’s therapy, solengepras, has demonstrated its potential to improve both motor and non-motor symptoms in a …
-
Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo
Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3 …
-
FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib
Enliven Therapeutics has reached an agreement with the US Food and Drug Administration (FDA) regarding the final protocol for the …
-
How advances in drug discovery are changing the path from research to clinical trials
Vini Jain, content and research team partner at Compound Vitality, explains how certain advancements in the preclinical stage are improving …
-
OCT SoCal 2026: Sound governance and collaboration lead the way as regulation percolates
Astutely managed clinical operations (clin-ops) are a foundational part of consistent and successful clinical trial execution. For the multiple stakeholders involved …
-
Viking Therapeutics begins study of oral VK2735 for obesity
Viking Therapeutics has commenced the second part of a clinical trial evaluating oral maintenance dosing schedules of its dual glucagon-like …
-
ViiV Healthcare’s Cabenuva beats daily oral ART in Phase IIIb trial
ViiV Healthcare’s long-acting HIV treatment Cabenuva showed superior rates of viral suppression compared with oral antiretroviral therapy (ART) in adults …
-
Eye implant sight improvements in GA continue for 36 months, pivotal study finds
Science Corporation’s subretinal implant and specialised glasses combination, PRIMA, has been shown to provide durable, long-term gains in vision to …
-
Parkinson’s disease market expected to reach $7.2bn across the 7MM by 2033
The Parkinson’s disease (PD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and …
-
AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
AbbVie and Genmab have reported positive topline data from the Phase III EPCORE DLBCL-2 trial of epcoritamab combined with standard …
-
First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody
Clinical-stage biotechnology company Vial has dosed the first patient in its Phase Ib clinical study evaluating interleukin-13 × thymic stromal …
-
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Vaxcyte’s stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its endpoints in a …
-
Clinical trial experts turn to AI and new partnerships to tackle growing trial complexity
Next month, senior-level speakers from leading pharma companies such as Roche, AstraZeneca and Novartis, along with speakers from emerging biotechs …
-
EADV26: Key late-stage readouts from the conference
In recent years, there has been an explosion in the range of therapies for immunological diseases, with the treatment paradigm …
